依托泊苷(Etoposide) - 药物靶点：Top II_在研适应症：膀胱癌，白血病，睾丸肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(−)-etoposide、4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)、4-demethylepipodophyllotoxin β-D-ethylideneglucoside

+ [26]

靶点

Top II

作用方式

抑制剂

作用机制

Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤免疫系统疾病内分泌与代谢疾病+ [6]

在研适应症

膀胱癌白血病睾丸肿瘤+ [22]

非在研适应症

急性白血病急性淋巴细胞白血病伴有骨髓发育不良相关变化的急性髓系白血病+ [36]

原研机构

Corden Pharma Latina SpA

在研机构

AstraZeneca PLCAstraZeneca KK

Nippon Kayaku Co., Ltd.

+ [7]

非在研机构

GSK Plc

Novartis AGCorden Pharma Latina SpA

+ [12]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1983-11-10),

小细胞肺癌睾丸肿瘤

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C29H32O13

InChIKeyVJJPUSNTGOMMGY-MRVIYFEKSA-N

CAS号33419-42-0

关联

1,751

项与依托泊苷相关的临床试验

NCT07850973

/ Not yet recruiting临床1/2期

Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors

The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer. The safety and effectiveness of this treatment combination therapies will also be studied.

开始日期2027-03-01

申办/合作机构-

NCT05403723

/ Suspended临床1期IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

开始日期2027-01-30

申办/合作机构

University of Maryland Baltimore

[+1]

CTIS2024-517295-37-00

/ Not yet recruiting临床3期IIT

Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

开始日期2026-12-01

申办/合作机构

Universities of Cologne

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

28,947

项与依托泊苷相关的文献（医药）

2027-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Molecular informatics guided assessment of triazole–thiadiazole conjugates as anti-leukemia entities: Computational fingerprinting, pharmacokinetic behavior and biological outcomes

Article

作者: Khowdiary, M M

Leukemia is a heterogeneous hematological malignancy that remains a major challenge in cancer therapy, highlighting the need for the development of structurally diverse and potent anticancer agents. In this study, a novel series of triazole-thiadiazole-based sulfonamide derivatives was designed and synthesized through a facile synthetic approach and characterized using ¹H NMR, ¹³C NMR, and HRMS techniques. The synthesized compounds were evaluated for their antiproliferative activity against HL-60, PLB-985, and K-562 leukemia cell lines. Among the investigated derivatives, the trifluoromethyl-substituted compound 6 emerged as the most promising candidate, exhibiting IC₅₀ values of 5.20 ± 0.10, 6.10 ± 0.20, and 8.30 ± 0.60 μM against HL-60, PLB-985, and K-562 cells, respectively, and showing greater potency than etoposide. Concentration-dependent cell viability studies further supported the antiproliferative potential of the lead compound. Molecular docking studies provided structural insights into the interactions of the active derivatives with leukemia-associated molecular targets, while ADMET profiling indicated generally favorable drug-like and pharmacokinetic properties. DFT calculations further elucidated the electronic characteristics and reactivity-related properties of the promising compounds. Collectively, the integrated in-vitro and in-silico findings identify the triazole-thiadiazole sulfonamide scaffold as a promising framework for leukemia drug discovery and highlight compound 6 as a lead candidate. Further target-specific biochemical validation, molecular dynamics simulations, selectivity studies, and in-vivo efficacy and safety investigations are warranted to establish its mechanism of action and therapeutic potential.

2026-12-31·Gut Microbes

Gut bacterial O -demethylation modulates systemic exposure to oral etoposide

Article

作者: Lee, Seongsoo ; Lee, Hyunwoo ; Sullivan, Peter ; Cooper, Bruce R. ; Ilktach, Giokdjen ; Shin, Jongoh ; Jeong, Hyunyoung ; Cho, Byung-Kwan ; Lee, Wooin ; Kyawt, Toe Ein ; Orjala, Jimmy ; Tripathi, Ashutosh ; Weilbaker, Holly A. ; Won, Kyoung-jae ; Armstrong, Abigail T. ; Ko, Yeonju

Gut microbial O-demethylation has been reported for plant-derived dietary compounds containing O-methylated aromatic(s). However, the significance of gut microbial O-demethylation in drug metabolism and disposition remains unexplored. This study examined 64 clinically used oral drugs containing one or more methoxylated aromatics for gut microbial O-demethylation using high-resolution mass spectrometry (HRMS). For 35 of the tested drugs, including the anticancer agent etoposide, we detected metabolites corresponding to O-demethylation (i.e., a mass difference of -14 and its multiples) when individual drugs were incubated with mouse cecal contents. We confirmed that the O-demethylated metabolite (M1) of the model drug etoposide is etoposide catechol using HRMS and proton nuclear magnetic resonance spectroscopy. By testing an in-house collection of 56 gut bacteria individually, we identified seven previously unknown gut bacterial species that exhibit etoposide O-demethylating activity. Etoposide anticancer therapy has been associated with an increased risk of acute myeloid leukemia. We demonstrated that M1 is more genotoxic to myeloid cells when it is orally administered to mice, whereas M1 is less cytotoxic against MCF-7 and HeLa cancer cells than the parent etoposide, suggesting that the gut microbiota may contribute to the secondary genotoxicity of etoposide via O-demethylation. Comparative pharmacokinetic analysis of orally administered etoposide in control and antibiotic-treated mice showed that systemic exposure to etoposide increased 1.9-fold, while M1 exposure decreased 3.7-fold in antibiotic-treated mice, suggesting that gut microbial O-demethylation is a significant determinant of etoposide metabolism and disposition. Collectively, our study reveals the prevalence of gut bacteria with O-demethylation activity, illustrates the contribution of gut microbial O-demethylation to altering drug efficacy and toxicity with the model drug etoposide, and provides a knowledge basis for in-depth characterization of other drugs identified as being susceptible to gut microbial O-demethylation.

2026-12-31·Future Science OA

Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?

Article

作者: Liu, Li ; Wu, Li-Peng ; Liu, Tao ; Min, Jie ; Sun, Si-Qin ; Xi, Heng

AIM:

To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.

OBSERVATION:

A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.

CONCLUSION:

This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.

1,971

项与依托泊苷相关的新闻（医药）

2026-10-22

·IO笔记

ESMO 2026 10.23开幕，值得关注的肺癌重磅研究

重磅！ESMO 2026摘要公开：46项中国口头临床研究，最新数据一篇看全从ESMO26 重磅LBA看未来创新药研发热点 ESMO LBA：中国研究独揽29项 ESMO 2026 肺癌值得关注的双抗、免疫联合ADC、围术期研究有哪些？ ESMO 2026 摘要上线，中国47个口头报告，来看看都有哪些公司/研究？ 10.23-27 西班牙马德里，ESMO会议；细分： ESMO上的双抗前菜 ESMO上的ADC前菜 ESMO2026：IBI363，PD-1/IL-2α-bias，一线NSCLC ORR高达86.4% ESMO上的PD-1(L1)/VEGF前菜 TCE T细胞衔接器：塔拉妥单抗一线维持治疗的3期DeLLphi-305研究入选ESMO2026主席研讨会 Presidential Symposium I 小细胞肺癌双抗 LBA3 - Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial 首个！安进临床III期成功（DeLLphi-305 -广泛期小细胞肺癌（ES-SCLC）患者的一线维持疗法阳性结果） Speakers Jacob Sands (Boston, United States of America) Duration 12 Minutes 研究设计：主要终点 OS； 3期 DeLLphi-304研究的OS更新 3808O - Tarlatamab in Previously Treated SCLC: Extended Follow-up of Overall Survival from the Phase 3 DeLLphi-304 Trial 细讲2025最重要的研究 DeLLPhi-304研究（小细胞肺癌双抗新药靶向CD3/DLL3） Speakers Charles M. Rudin (New York, United States of America) Duration 10 Minutes DeLLphi-303研究 PD-1±ADC LBA66 - Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study Speakers Caicun Zhou (Shanghai, China) Duration 10 Minutes 2026ASCO公布的 OptiTROP-Lung06 数据亮眼！ PFS HR达到0.35：科伦博泰公布TROP2 ADC+PD-1一线肺癌临床数据 Rapid Oral session 快速口头报告专场 2631RO - First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study 中文标题：一线 BAT8008（TROP2-ADC）联合 BAT1308（抗 PD-1）治疗晚期非小细胞肺癌：一项多中心 II 期研究结果 Speakers Shao Dong Hong (Guangzhou, China) Duration 5 Minutes 2614O - Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020) Speakers Chantal Decroisette (Lyon, France, CEDEX) Duration 10 Minutes 广泛期小细胞肺癌斯鲁利单抗美国人群数据 3809O - Randomized trial of serplulimab or atezolizumab plus chemotherapy in USA patients with extensive-stage small cell lung cancer (ASTRIDE) Speakers David R. Gandara (Sacramento, United States of America) Duration 10 Minutes 双抗/三抗摘要号：4156RO 研究名称（英文）：Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM phase II study 研究名称（中文）：依沃西单抗联合化疗一线治疗复发 / 转移性胸腺癌：iTHYM II 期研究中期数据讲者：侯雪中山大学肿瘤防治中心报告类型：Rapid Oral session 摘要号：2616RO 研究名称（英文）：A phase 2 study of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer (NSCLC) 研究名称（中文）：全球首创 PD-1/VEGF/CTLA-4 三特异性抗体 CS2009 治疗晚期非小细胞肺癌的 II 期临床研究讲者：熊安稳同济大学附属东方医院报告类型：Rapid Oral session Rapid Oral session 快速口头报告专场 2646RO - A phase 2 trial of JS207 (PD-1/VEGF bispecific antibody) plus chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC) 中文标题： JS207（PD-1/VEGF 双特异性抗体）联合化疗一线治疗晚期非小细胞肺癌（NSCLC）的 II 期临床试验君实双抗 Speakers Linlin Wang (Jinan, China) Duration 5 Minutes WCLC2026: PD-1/VEGF双特异性抗体JS207联合化疗治疗不可切除III期非小细胞肺癌疗效如何？围术期免疫： Neotorch 研究最终分析 LBA64 - Toripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch study Speakers Shun Lu (Shanghai, China) Duration 10 Minutes 围术期免疫3期 IMpower030 研究阴性，功败垂成＆盘点同类研究数据 KEYNOTE-671 研究 2519O - Association of Biomarkers With Efficacy in the Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) Plus Neoadjuvant Chemotherapy (Chemo) in Early-Stage Non–Small-Cell Lung Cancer (NSCLC) Speakers Marina C. Garassino (Chicago, United States of America) 2511RO - Final Analysis of Adjuvant Pembrolizumab (Pembro) in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 Study SpeakersMary E. O'Brien (London, United Kingdom) Duration 5 Minutes 2026ASCO 肺癌围术期研究术后辅助治疗III期研究（ALCHEMIST研究阴性结果） MDT-BRIDGE研究ctDNA清除 LBA62 - ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE Speakers Jonathan Spicer (Montreal, Canada) Duration 5 Minutes CTONG 1804研究手术转化数据 LBA65 - Surgical Conversion and Survival Outcomes After Induction Chemoimmunotherapy in Potentially Resectable or Unresectable Stage III NSCLC: Preliminary Results from the Prospective Phase II Study (CTONG 1804 Part 3). Speakers Yi Pan (Guangzhou, China) Duration 5 Minutes 热点方向：不可切除肺癌免疫治疗的转化治疗探索＆盘点已有研究数据 PD-1+BTLA抗体新辅助治疗 2574RO - Neoadjuvant toripalimab plus chemotherapy with or without tifcemalimab (anti-BTLA antibody) in potentially resectable stage III non-small cell lung cancer (LungMate-014): a randomized, phase II trial Speakers Peng Zhang (Shanghai, China) Duration 5 Minutes 延申： 2026ASCO-晚期NSCLC治疗进展 WCLC 2026肺癌研究全景：12项重要口头报告深度解读 2026ASCO 双抗的相关研究数据有哪些？双抗玩家26年越来越热闹（PD-1/VEGF等） 2025ESMO: 肺癌值得关注的重磅研究备注：部分图片、信息等来自网络，侵删。部分分析借助AI整理。仅代表个人观点。仅供学术交流使用。转载请标明出处。（本文发布24小时后允许转载）相关参考文献资料等均陆续更新至知识星球中。保持更新，随缘加入！一路相伴，共同成长！

2026-10-21

·医事英明

小细胞肺癌患者新机会！多个在研新药临床试验招募，初治/经治均可评估！

小细胞肺癌（SCLC）恶性程度高、进展快，很多患者与家属在求医路上不断寻找更优的治疗方案。随着新药研发不断突破，多款针对小细胞肺癌的创新药物临床试验正在招募患者，初治广泛期小细胞肺癌、一线治疗后复发进展的经治患者，以及EGFR突变NSCLC转化而来的小细胞肺癌人群，均有对应的项目可以评估。临床试验，为陷入治疗困境的家庭，提供了接触前沿新药的机会。下文整理目前正在招募的部分小细胞肺癌临床试验项目，供患者和家属参考。 ⚠️重要提示：临床试验有严格的入组、排除标准，并非所有患者都能直接入组，需要完善筛查评估，最终能否入组由研究医生判定。一、初治广泛期小细胞肺癌项目✅项目1：ZG006（CD3×DLL3×DLL3三特异性抗体）药物简介：ZG006是CD3×DLL3×DLL3三特异性抗体药物。治疗方案：试验组：ZG006+阿得贝利单抗+依托泊苷+卡铂核心入组要点年龄≥18且≤75周岁组织学/细胞学确诊广泛期小细胞肺癌肿瘤组织、细胞学或血液学证实EGFR敏感突变主要排除既往联合或序贯使用过抗DLL3、抗CD3靶点药物（含研究用药），以及其他免疫检查点抑制剂未经治疗的脑转移排除；经治疗后病情稳定的脑转移可参与筛选✅项目2：QLC5508注射液（B7-H3靶向ADC）药物简介：QLC5508是创新型B7-H3靶向抗体药物偶联物（ADC）。治疗方案试验组：QLC5508+QL2107，诱导期给药4周期，之后维持期继续QLC5508+QL2107 对照组：替雷利珠单抗+卡铂/顺铂+依托泊苷，诱导期4周期，后续维持替雷利珠单抗核心入组要点年龄≥18周岁，性别不限组织学/细胞学确诊广泛期小细胞肺癌既往未接受过局部晚期/转移性肿瘤系统性治疗主要排除转化型NSCLC演变的SCLC、EGFR突变NSCLC转化SCLC、混合型SCLC/NSCLC排除中脑、脑桥、延髓、脊髓转移；软脑膜转移、脑干转移患者排除二、经治小细胞肺癌项目（一线治疗后复发/进展）✅项目1：ZG006注射液药物简介：ZG006，CD3×DLL3×DLL3三特异性抗体药物治疗方案：试验组ZG006，对照组化疗方案核心入组要点年龄≥18岁且≤75岁确诊小细胞肺癌，至少经过2个周期一线含铂联合免疫检查点抑制剂治疗后进展/复发的广泛期SCLC主要排除复合型SCLC、转化型SCLC排除既往使用过靶向DLL3或CD3的药物（含研究性药物）✅项目2：BL0020‑102注射液（新一代纳米偶联PDC新药）药物简介：BL0020新一代纳米偶联PDC新药治疗方案：试验组BL0020注射液联合特瑞普利单抗核心入组要点年龄≥18岁，体重＞45kg，男女不限广泛期SCLC，仅接受过一线铂类系统治疗后复发或进展主要排除无化疗间隔CTFI＜30天（末次铂类化疗给药到疾病进展时间），无论是否接受免疫维持治疗✅项目3：BL0020‑101注射液药物简介：BL0020新一代纳米偶联PDC新药治疗方案：试验组BL0020注射液单药核心入组要点年龄≥18岁，性别不限 ECOG体力评分0‑1分主要排除不稳定或有症状脑转移排除无化疗间隔CTFI＜30天排除✅项目4：SSGJ‑706注射液（抗PD‑1/PD‑L1双特异抗体）药物简介：重组双特异抗体，同时靶向PD‑1和PD‑L1 治疗方案：试验组SSGJ‑706注射核心入组要点年龄18‑75周岁可提供5张病理切片；TPS/CPS未知可在筛选期检测，检测结果不影响筛选资格✅项目5：IMM2510（PD‑L1/VEGF双特异性抗体）药物简介：靶向PD‑L1和VEGF的双特异性抗体‑受体重组蛋白药物，皮下注射给药治疗方案：试验组IMM2510皮下注射核心入组要点年龄18‑75岁，ECOG 0‑1分局部晚期/转移性实体瘤（头颈部肿瘤、皮肤癌、胆管癌、胰腺癌等除外）主要排除存在静脉血栓肿瘤负荷大：单个肿瘤≥7.5cm，或者病灶总径之和＞10cm✅项目6：AL8326片（多靶点RTK抑制剂）药物简介：多靶向酪氨酸激酶抑制剂治疗方案：试验组AL8326片，对照组安慰剂，随机比例2:1核心入组要点年龄≥18岁，男女均可至少二线系统治疗后复发进展的小细胞肺癌主要排除脑转移患者排除既往使用AL8326片肿瘤负荷＞100mm✅项目7：CS231295片（小分子多靶点激酶抑制剂）药物简介：小分子多靶点蛋白激酶抑制剂，抑制VEGFRs、PDGFRs等靶点治疗方案：试验组CS231295片核心入组要点年龄≥18岁，男女均可主要排除脑膜转移（脑胶质瘤除外）单个病灶＞10cm✅项目8：BL0020‑201注射液药物简介：BL0020新一代纳米偶联PDC新药治疗方案：试验组BL0020注射液核心入组要点年龄≥18岁，男女不限初始诊断EGFR突变型NSCLC，经EGFR‑TKI治疗后转化为SCLC主要排除有症状脑转移、癌性脑膜炎、脑干转移、脊髓压迫排除；脑转移稳定可评估入组三、写给患者与家属小细胞肺癌的治疗一直在迭代创新，临床试验给一部分患者带来接触前沿新药的机会。 ⚠️重要提醒临床试验有严谨的筛选流程，不是所有患者都可以入组，需要结合病理报告、影像资料、既往治疗史、身体状态综合评估，最终入组资格由研究医生判定。参与临床试验前，务必充分了解项目的获益、潜在风险，仔细阅读知情同意书。本文仅作为临床试验科普招募参考，不替代临床医生诊疗建议，不能作为自行用药依据。如果您或者家人是小细胞肺癌，想评估是否匹配临床试验，可以提交病历资料，帮您初筛评估适合的项目。报名咨询方式需评估自身或家属是否符合本研究入组条件，可私信本公众号后台，发送：病理类型、分期、既往治疗线数、近期复查报告，工作人员将为您完成免费初步适配评估。肿瘤患者申请参加临床试验须知：参与临床试验的患者，可以免费用试验新药，与试验相关的检查也是免费的。目前有CAR-T、TIL等细胞疗法，PD-1/PD-L1等免疫治疗药物，小分子抑制剂、双抗、单抗、ADC等靶向药物的临床试验正在进行中。正在招募肺癌、食管癌、肝癌、胃癌、结直肠癌、宫颈癌、卵巢癌、乳腺癌、胆管癌、子宫内膜癌、黑色素瘤、肉瘤、恶性血液疾病、淋巴瘤等各种恶性肿瘤,想要了解或者参加临床试验项目，可以咨询我们医学部的老师。联系电话13671049387张老师微信13718807158

2026-10-21

·搜狐新闻

ADC药物QLC5508联合PD-1抑制剂QL2107治疗小细胞肺癌

本临床药物为B7-H3 ADC药物；目前招募广泛期小细胞肺癌（ES-SCLC）患者；年龄≥18岁；既往未接受过针对ES-SCLC的系统性治疗；ECOG PS为0～1分，并且在首次给药前2周没有恶化；排除转化型SCLC或混合型SCLC NSCLC组织学类型；排除其他原发性实体瘤病史；排除既往接受过同种异体骨髓移植或实体器官移植的参与者；脑转移患者需治疗后稳定4周以上；全国多中心。研究中心上海安徽合肥、蚌埠、阜阳江西南昌、赣州广东汕头、广州、中山浙江杭州、金华、温州江苏南京、徐州、南通、苏州北京辽宁沈阳吉林长春黑龙江哈尔滨河北石家庄、承德、保定天津云南昆明陕西西安新疆乌鲁木齐陕西西安山西太原、运城重庆山东济南、滨州、青岛、济宁、潍坊湖北武汉湖南长沙河南郑州、新乡、洛阳福建福州、厦门、泉州内蒙古赤峰甘肃兰州四川宜宾贵州贵阳、遵义广西南宁、桂林具体启动情况以后期咨询为准试验名称注射用QLC5508联合QL2107对比替雷利珠单抗联合含铂化疗一线治疗广泛期小细胞肺癌的随机、开放、多中心III期临床研究。试验药物 B7-H3（CD276）是B7家族的一员，在T细胞反应中起免疫调节作用，被认为是癌症免疫治疗的潜在新靶点。多项研究证实，B7-H3在大多数正常组织中低表达，广泛表达于前列腺癌、胰腺癌、乳腺癌、结直肠癌、肺癌、食管癌和卵巢癌等多种人类恶性肿瘤。此外，B7-H3还与肿瘤细胞增殖、转移和治疗耐药相关及患者预后不佳有关。 QLC5508（MHB088C）是齐鲁制药从明慧医药引进的一款创新B7-H3 ADC药物，通过特异性结合肿瘤细胞表面的B7-H3，将强效的拓扑异构酶抑制剂有效载荷精准递送至肿瘤内部，从而实现高效的抗肿瘤活性，其有效载荷效力比传统药物高5至10倍。目前，QLC5508已在复发性小细胞肺癌、晚期食管鳞癌和转移性去势抵抗性前列腺癌等适应症领域先后被国家药品监督管理局药品审评中心纳入突破性治疗品种，展现了极大的临床开发潜力。 QL2107是齐鲁制药研发的新型帕博利珠单抗生物类似药，针对的是转移性非鳞状非小细胞肺癌。这种癌症的治疗往往具有挑战性，而QL2107的研发为这类患者提供了新的治疗希望。帕博利珠单抗（英文通用名：Pembrolizumab；商品名：可瑞达）是默沙东开发的PD-1抑制剂，可阻断PD-1与其配体PD-L1和PD-L2之间的相互作用，释放PD-1信号通路介导的免疫反应抑制，从而激活可能影响肿瘤细胞和健康细胞的T淋巴细胞，进而增强人体免疫系统发现和消灭癌细胞的能力。研究药物：注射用QLC5508联合QL2107（III期）登记号：CTR20263716 试验类型：对照试验（VS 替雷利珠单抗联合含铂化疗）适应症：广泛期小细胞肺癌（一线）用药周期注射用QLC5508的规格：50mg/瓶；用法用量：2.4mg/kg, 静脉滴注；用药时程：每3周1次，直到疾病进展或达到其他终止治疗的标准。 QL2107注射液的规格：100mg/4ml；用法用量：200mg，静脉滴注；用药时程：每3周1次，直到疾病进展或达到其他终止治疗的标准。对照药如下：替雷利珠单抗注射液的规格：100mg(10ml)/瓶；用法用量：200mg，静脉输注；用药时程：每3周1次，直到疾病进展或达到其他终止治疗的标准。卡铂注射液的规格：10ml:100mg；用法用量：AUC=5mg/ml/min，静脉输注；用药时程：每3周为一个治疗周期，每周期第1天给药，共4个周期。注射用顺铂（冻干型）的规格：（1）10mg，（2）20mg；用法用量：75mg/m2，静脉滴注；用药时程：每3周为一个治疗周期，每周期第1天给药，共4个周期。依托泊苷注射液的规格：5ml:100mg；用法用量：100mg/m2，静脉滴注；用药时程：每3周为一个治疗周期，每周期第1-3天给药，共4个周期。【重要提示】印塔健康旗下公众号【全球好药资讯】所有文章信息仅供参考，具体治疗谨遵医嘱！返回搜狐，查看更多

抗体药物偶联物临床结果突破性疗法临床3期生物类似药

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma International GmbH	1983-11-10
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma International GmbH	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期神经内分泌癌	临床3期	日本	AstraZeneca KK	2023-12-01
胃肠胰神经内分泌肿瘤	临床3期	日本	AstraZeneca KK	2023-12-01
小细胞癌	临床3期	日本	AstraZeneca KK	2023-12-01
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2026	N/A	生殖细胞和胚胎肿瘤	29	Ifosfomide, carboplatin, etoposide (ICE) regimen	鏇範襯積蓋鑰淵選簾構(獵顧餘網構積積憲築襯) = 遞壓範膚蓋鏇範艱簾鬱糧壓糧餘襯糧夢艱觸簾 (獵糧製衊憲鏇鬱鹽鬱衊 ) 更多	积极	2026-10-23
IGCS2026	N/A	妊娠滋养细胞疾病	19	Escalated Etoposide and Cisplatin	簾壓糧鬱遞醖壓糧築積(鹹鏇鏇繭衊餘廠襯窪廠) = 製製觸鹹壓膚鏇繭醖齋選獵鬱繭築顧襯築窪繭 (壓廠淵範觸壓繭餘膚鑰 )	积极	2026-10-01
				Escalated Etoposide and Cisplatin (choriocarcinoma)	觸鹹獵壓蓋夢願築鹽餘(鹽淵繭鹹衊糧繭鬱廠鑰) = 鹹顧鬱壓遞膚觸夢鹽艱壓積鬱鏇襯製遞鹽鏇艱 (醖窪鬱淵膚鑰糧襯襯獵 ) 更多
IMS2026	N/A	多发性骨髓瘤	35	Busulfan+Cyclophosphamide+Etoposide	範觸願糧壓遞繭鏇築繭(觸夢夢廠製壓顧遞艱築) = 鬱膚壓構醖獵選選鹹顧廠選淵廠製範範繭獵壓 (網齋衊遞簾網範餘鹽蓋 ) 更多	积极	2026-09-23
				High-Dose Melphalan	範觸願糧壓遞繭鏇築繭(觸夢夢廠製壓顧遞艱築) = 壓壓鏇築夢淵憲淵範簾廠選淵廠製範範繭獵壓 (網齋衊遞簾網範餘鹽蓋 ) 更多
WCLC2026	N/A	生殖细胞和胚胎肿瘤	114	Bleomisin-etoposide-cisplatin chemotherapy (Nonseminomatous)	網艱範窪廠廠鏇願獵獵(顧獵膚獵選積選遞淵蓋) = 鑰窪製糧鹽廠網襯獵艱製網艱糧淵製顧醖遞顧 (獵願蓋艱餘鹽淵窪製蓋, 7.37)	不佳	2026-09-12
WCLC2026	N/A	广泛期小细胞肺癌一线 \| 二线	4,470	Cisplatin-based or carboplatin-based therapy + Cisplatin-basedapiecarboplatin-based therapy	廠餘膚鹹鏇壓窪蓋餘鹽(鹹網製鏇淵範鬱範襯廠) = 積憲壓製膚衊鹹構積糧簾鏇鹹範鹹艱獵遞壓夢 (顧膚襯鹽夢壓製膚襯製 ) 更多	积极	2026-09-12
				Etoposide-based regimensTopotecan-based regimens + Etoposide-based regimensTopotecan-based regimens + Etoposide-based regimensTopotecan-based regimens	廠餘膚鹹鏇壓窪蓋餘鹽(遞襯餘艱網選淵築夢積) = 壓選壓觸艱鏇廠窪醖艱鏇糧夢遞糧廠糧網廠壓 (願鬱糧窪鬱選鏇簾廠壓 ) 更多
WCLC2026	N/A	广泛期小细胞肺癌一线	97	Carboplatin-Etoposide-Atezolizumab	鹽遞築夢淵鏇鏇鹽憲蓋(鹽衊淵淵衊獵齋顧選簾) = 簾糧顧選獵範衊餘遞選顧淵鹹餘鏇齋構鬱鑰餘 (觸鹹鏇憲醖願廠糧憲鹽 ) 更多	积极	2026-09-12
CSCO2026	N/A	非精原细胞生殖细胞肿瘤	64	High Dose Chemotherapy (HDCT) + Peripheral Blood Stem Cell Transplantation (PBSCT)	膚蓋鏇願夢夢壓淵願鹹(衊願繭簾夢觸願遞醖壓) = 鹽蓋壓鹹積範廠選鑰淵積獵願廠蓋願遞餘獵構 (鹽襯繭齋築齋顧觸願選 ) 更多	积极	2026-09-11
ChiCTR1800015883 (Pubmed \| Blood)	临床3期	急性髓性白血病	224	Low-dose cytarabine, mitoxantrone or idarubicin, and granulocyte colony-stimulating factor	築醖積壓壓鏇齋壓繭願(壓襯窪衊構繭淵壓蓋顧) = 餘餘餘艱醖艱網網築壓膚壓鹹醖遞憲襯顧夢鏇 (廠齋鬱憲製鹹齋鬱選襯 ) 更多	非劣	2026-07-02
				Cytarabine, daunomycin, and etoposide	築醖積壓壓鏇齋壓繭願(壓襯窪衊構繭淵壓蓋顧) = 艱糧獵鏇糧網糧網顧製膚壓鹹醖遞憲襯顧夢鏇 (廠齋鬱憲製鹹齋鬱選襯 ) 更多
NCT01783535 (CTgov)	临床2期	单侧视网膜母细胞瘤 \| 视网膜母细胞瘤	174	focal therapy+carboplatin+PEG-filgrastim+filgrastim+vincristine+Topotecan (Stratum A)	夢夢積鏇鬱襯築遞淵觸(積餘選觸築範鬱簾積糧) = 廠鑰築壓夢膚廠餘齋廠夢築窪構夢憲蓋鏇餘餘 (蓋鏇憲積鹹壓廠構鹹選, 範齋選遞願積範醖艱獵 ~ 簾構襯網糧夢鏇遞憲範) 更多	-	2026-06-29
				focal therapy+etoposide+carboplatin+PEG-filgrastim+Filgrastim+vincristine+Topotecan (Stratum B)	夢夢積鏇鬱襯築遞淵觸(積餘選觸築範鬱簾積糧) = 窪鹽觸壓積衊糧顧遞獵夢築窪構夢憲蓋鏇餘餘 (蓋鏇憲積鹹壓廠構鹹選, 製壓齋淵範夢遞範膚繭 ~ 鏇衊夢糧壓鹹艱憲觸築) 更多
ASCO_Breakthrough2026	N/A	神经内分泌癌	37	Definitive chemoradiotherapy (limited-stage disease)	衊壓製選襯廠廠醖糧積(廠夢構願夢艱餘顧鏇廠) = 範願鬱鏇衊壓築簾遞醖鹹夢醖膚襯獵構遞醖願 (鬱願齋築糧衊製鹽夢廠 ) 更多	积极	2026-06-25
				Platinum-etoposide chemotherapy (extensive-stage disease)	鹽糧獵膚觸廠憲製築網(窪淵廠壓築壓鬱範膚選) = 廠衊夢願膚廠壓網範遞醖鬱艱獵獵壓餘鏇製選 (艱構夢構構襯淵淵壓觸 ) 更多